TELA - Tela Bio Inc

TELA - Tela Bio Inc

https://www.telabio.com

Momentum: Bearish

Recent News

Powered by Alpha Vantage

TELA Bio, Inc. ( TELA ) Reports Q2 Loss, Lags Revenue Estimates

Zacks Commentary • 1 month ago • score: 0.05

TELA Bio (TELA) delivered earnings and revenue surprises of -22.22% and -1.72%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 )

GlobeNewswire • 1 month ago • score: 0.33

MALVERN, Pa., Aug. 08, 2025 ( GLOBE NEWSWIRE ) -- TELA Bio, Inc. ( "TELA Bio" ) ( NASDAQ: TELA ) , a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Compensation Committee of the Board of Directors of TELA ...

TELA Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635 ( c ) ( 4 )

GlobeNewswire • 3 months, 1 week ago • score: 0.39

MALVERN, Pa., June 06, 2025 ( GLOBE NEWSWIRE ) -- TELA Bio, Inc. ( "TELA Bio" ) ( NASDAQ: TELA ) , a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration ...

TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 )

GlobeNewswire • 4 months ago • score: 0.33

MALVERN, Pa., May 09, 2025 ( GLOBE NEWSWIRE ) -- TELA Bio, Inc. ( "TELA Bio" ) ( NASDAQ: TELA ) , a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Compensation Committee of the Board of Directors of TELA ...

TELA Bio, Inc. ( TELA ) Reports Q1 Loss, Tops Revenue Estimates

Zacks Commentary • 4 months ago • score: -0.01

TELA Bio (TELA) delivered earnings and revenue surprises of -19.05% and 6.13%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

TELA Bio to Announce First Quarter 2025 Financial Results

GlobeNewswire • 4 months, 4 weeks ago • score: 0.24

MALVERN, Pa., April 17, 2025 ( GLOBE NEWSWIRE ) -- TELA Bio, Inc. ( "TELA Bio" ) ( NASDAQ: TELA ) , a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will report first quarter 2025 financial ...

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

Source: Snapshot

TELA Bio, Inc., a medical technology company, focuses on the design, development and commercialization of tissue reinforcement materials to address unmet needs in soft tissue reconstruction. The company is headquartered in Malvern, Pennsylvania.

52W High

$3.26

52W Low

$0.87

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

0.84

Valuation

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

-5.01

EV/Revenue (<3 favorable)

0.93

P/S (TTM) (<3 favorable)

0.84

P/B (<3 favorable)

6.86

Ownership

Balanced

Source: Overview

Insiders (1–5% typical)

8.98%

Institutions (25–75% balanced)

73.05%

Shares Outstanding

39,616,400

Float

18,416,100

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

75,323,000

Gross Profit (TTM)

51,076,000

EPS (TTM)

-1.06

Profit Margin (>10% good)

-0.54%

Operating Margin (TTM) (higher better)

-0.45%

ROE (TTM) (>15% strong)

-6.76%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

0.26

Momentum

Bearish momentum

Value

-0.0607

Previous

-0.0585

Trend

Falling

Signal Cross

No cross

As of

Sep. 12, 2025